분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-02-09 06:11:37 , Hit : 1327
 Nano-CRISPR Packages Attain 90% Delivery Rate with Engineered Cas9

GEN News Highlights

February 8, 2017

http://www.genengnews.com/gen-news-highlights/nano-crispr-packages-attain-90-delivery-rate-with-engineered-cas9/81253848?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20170208


A new nanoparticle-based delivery system boosts gene editing efficiency. The delivery system, which was developed through the coengineering of Cas9 protein and carrier nanoparticles, helps CRISPR/Cas9 cross the cell membrane and enter the nucleus while avoiding entrapment by cellular machinery. [Rotello Lab, UMass Amherst]

Neither the cell membrane nor the cytoplasm nor the nuclear membrane stays these couriers from the swift completion of their appointed rounds. “These couriers” are nanoparticles that carry Cas9-ribonucleoprotein (RNP) complexes into the cytoplasm and nucleus of target cells, and do so with uncommon efficiency.

Newly developed by scientists in Vincent Rotello's laboratory at the University of Massachusetts, Amherst, the nanoparticles are significant because they could enhance the effectiveness of the already powerful CRISPR/Cas9 gene-editing tool, which holds enormous promise for treating genetic diseases such as cystic fibrosis, muscular dystrophy, and hemophilia. To work well, however, CRISPR/Cas9 must be delivered safely across the cell membrane and into its nucleus, a difficult process that can trigger the cell's defenses. These defenses can "trap" CRISPR/Cas9, greatly reducing its treatment potential.

Details about the new delivery system recently appeared in the journal ACS Nano, in an article entitled, “Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.” The article describes how the new delivery method depends on an engineered version of the Cas9 protein, named Cas9En, and carrier nanoparticles that have been designed to be compatible with CasEn.

“Here, we report a remarkably highly efficient (∼90%) direct cytoplasmic/nuclear delivery of Cas9 protein complexed with a [single] guide RNA (sgRNA) through the coengineering of Cas9 protein and carrier nanoparticles,” wrote the article’s authors. “This construct provides effective (∼30%) gene editing efficiency and opens up opportunities in studying genome dynamics.”

The Rotello laboratory's experiment leader, Rubul Mout, Ph.D., pointed out that since CRISPR's potential was first discovered in 2012, gene editing or genome engineering has quickly become an intense research topic in biology and medicine. The goal is to treat otherwise incurable genetic diseases by manipulating diseased genes. "However, to achieve this,” noted Dr. Mout, “biotech and pharmaceutical companies are constantly searching for more efficient CRISPR delivery methods."

"CRISPR has two components: a scissor-like protein called Cas9, and an RNA molecule called sgRNA that guides Cas9 to its target gene,” he explained. “Once the Cas9-sgRNA pair gets to the destination gene in the nucleus, it can interrogate its genetic mistakes and correct them with the help of the host cell's repair machinery."

But the direct and efficient delivery of Cas9-RNP into the cytosol followed by translocation to the nucleus has remained a challenge.

"By finely tuning the interactions between engineered Cas9En protein and nanoparticles, we were able to construct these delivery vectors,” said Dr. Mout. “The vectors carrying the Cas9 protein and sgRNA come into contact with the cell membrane, fuse, and release the Cas9-sgRNA directly into the cell cytoplasm.

"Cas9 protein also has a nuclear guiding sequence that ushers the complex into the destination nucleus. The key is to tweak the Cas9 protein," he continued. "We have delivered this Cas9 protein and sgRNA pair into the cell nucleus without getting it trapped on its way. We have watched the delivery process live in real time using sophisticated microscopy."

90% cytosolic/nuclear delivery is a huge improvement compared to others methods, the researchers pointed out. The researchers also indicated that the Cas9En they developed may also serve as a platform for delivery of a variety of other materials such as polymers, lipid nanoparticles, or self-assembling peptides.

"Now that we have achieved efficient gene editing in cultured cells, we are aiming to edit genes in pre-clinical animal models,” Vincent Rotello, Ph.D., remarked. “We are also interested in gene editing for adoptive therapies, where a diseased cell is isolated from a patient, corrected by CRISPR in the lab, and delivered back to the patient."

Apart from gene editing, the new delivery method may have other uses. For example, another important issue in biology and medicine is tracking DNA and RNA inside cells. Recently, CRISPR has been used to aid in this research. Moumita Ray, Ph.D., another researcher in the Rotello laboratory, added, "Our method allows the precise monitoring of Cas9 protein movement inside a cell, opening new opportunities in genomic research."







987   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1071
  Nano-CRISPR Packages Attain 90% Delivery Rate with Engineered Cas9  이성욱 2017/02/09 1327
985   유전자 치료로 청력 되살린다  이성욱 2017/02/08 1349
984   바이러스들도 서로 소통..“상황에 따라 감염방식 결정”  이성욱 2017/01/24 1133
983   Oligonucleotide Therapeutics Near Approval  이성욱 2017/01/10 1168
982   Off Switch Found for Common Version of the CRISPR-Cas9 System  이성욱 2017/01/02 994
981   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 819
980   RNA Modification Helps Drosophila Straighten Up and Fly Right  이성욱 2016/12/10 886
979   Anti-CRISPR Protein Is Gene Editing “Off-Switch”  이성욱 2016/12/10 1890
978   Could Gene Therapy Work for Alzheimer’s Disease?  이성욱 2016/10/12 1158
977   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1146
976   DNA Can Be Edited Without Being Cut  이성욱 2016/08/30 1418
975   Using RNA to Amplify RNA  이성욱 2016/08/16 1031
974   CRISPR: No Cutting Required  이성욱 2016/08/06 1636
973   “Kissing Disease” Virus Promotes Malignant Breast Cancer Development  이성욱 2016/08/03 1038
972   Lytic and latent viral replication prevented with CRISPR/Cas9  이성욱 2016/07/27 918
971   Chinese Scientists To Test Gene Modifying Technique ‘CRISPR’ On Humans For The First Time  이성욱 2016/07/27 1094
970   FDA OKs AbbVie's once-daily Viekira XR for HCV-1  이성욱 2016/07/27 907
969   [미국] 유전자가위 규제 마련 지연과 기업들의 움직임  이성욱 2016/07/21 1102
968   5년새 20배 성장 `유전자치료제` 시장..경쟁력 확보 필수  이성욱 2016/07/21 986

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN